We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Albemarle (ALB - Free Report) ended the recent trading session at $77.07, demonstrating a +1.76% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.01%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.05%.
Shares of the specialty chemicals company have appreciated by 27.51% over the course of the past month, outperforming the Basic Materials sector's gain of 1.67%, and the S&P 500's gain of 5.37%.
The investment community will be closely monitoring the performance of Albemarle in its forthcoming earnings report. The company is scheduled to release its earnings on July 30, 2025. On that day, Albemarle is projected to report earnings of -$0.83 per share, which would represent a year-over-year decline of 2175%. Meanwhile, our latest consensus estimate is calling for revenue of $1.23 billion, down 13.67% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$2.02 per share and revenue of $4.86 billion. These totals would mark changes of +13.68% and -9.54%, respectively, from last year.
Any recent changes to analyst estimates for Albemarle should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 24.78% lower. Albemarle is currently a Zacks Rank #4 (Sell).
The Chemical - Diversified industry is part of the Basic Materials sector. This industry, currently bearing a Zacks Industry Rank of 228, finds itself in the bottom 8% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Albemarle (ALB) Rises As Market Takes a Dip: Key Facts
Albemarle (ALB - Free Report) ended the recent trading session at $77.07, demonstrating a +1.76% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.01%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.05%.
Shares of the specialty chemicals company have appreciated by 27.51% over the course of the past month, outperforming the Basic Materials sector's gain of 1.67%, and the S&P 500's gain of 5.37%.
The investment community will be closely monitoring the performance of Albemarle in its forthcoming earnings report. The company is scheduled to release its earnings on July 30, 2025. On that day, Albemarle is projected to report earnings of -$0.83 per share, which would represent a year-over-year decline of 2175%. Meanwhile, our latest consensus estimate is calling for revenue of $1.23 billion, down 13.67% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$2.02 per share and revenue of $4.86 billion. These totals would mark changes of +13.68% and -9.54%, respectively, from last year.
Any recent changes to analyst estimates for Albemarle should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 24.78% lower. Albemarle is currently a Zacks Rank #4 (Sell).
The Chemical - Diversified industry is part of the Basic Materials sector. This industry, currently bearing a Zacks Industry Rank of 228, finds itself in the bottom 8% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.